Prespecified second interim analysis of a phase 3 RCT in 419 adults with lenalidomide-refractory myeloma: cilta-cel improved overall survival vs standard care (HR 0.55, p=0.0009; medians not reached); grade 4 adverse events were more frequent (75% vs 56%).
RCTn = 419
Einsele et al. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial